28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Abbvie
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Genentech
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.

University of Michigan Medical School
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.

The Walter and Eliza Hall Institute of Medical Research
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Mcgill University
Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.

University of Minnesota Minneapolis
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.

University of Minnesota
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.

University of Washington
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.

The Walter and Eliza Hall Institute of Medical Research
Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.

University of Pittsburgh
Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor.

Tianjin University
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.

University of Minnesota
Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.

China Pharmaceutical University
Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy.

Shandong First Medical University & Shandong Academy of Medical Sciences
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.

Yancheng Teachers University
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

Abbott Laboratories
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.

Abc Pharma
Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.

Amgen
Discovery of 3,5-Dimethyl-4-Sulfonyl-1

China Pharmaceutical University
Discovery and optimization of covalent Bcl-xL antagonists.

Astrazeneca
The chemical biology of apoptosis: Revisited after 17 years.

Tsinghua University
Clinical candidates modulating protein-protein interactions: The fragment-based experience.

Taros Chemicals
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.

Soochow University
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.

University of Maryland
Substituted quinolines as PDE-10 inhibitors

Sunovion Pharmaceuticals
Synthesis and target identification of hymenialdisine analogs.

Genomics Institute of The Novartis Research Foundation
AR-709-An Investigational diaminopyrimidine: Inhibition, Binding and Mode of Action.

Arpida